Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.18
HOLX's Cash-to-Debt is ranked lower than
76% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. HOLX: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
HOLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 3.92 Max: No Debt
Current: 0.18
Equity-to-Asset 0.35
HOLX's Equity-to-Asset is ranked lower than
84% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. HOLX: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
HOLX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.7 Max: 0.88
Current: 0.35
0.02
0.88
Interest Coverage 9.09
HOLX's Interest Coverage is ranked lower than
74% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.83 vs. HOLX: 9.09 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s Interest Coverage Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 71.1
Current: 9.09
0.55
71.1
Piotroski F-Score: 5
Altman Z-Score: 1.68
Beneish M-Score: -1.87
WACC vs ROIC
4.84%
17.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 47.20
HOLX's Operating Margin % is ranked higher than
98% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. HOLX: 47.20 )
Ranked among companies with meaningful Operating Margin % only.
HOLX' s Operating Margin % Range Over the Past 10 Years
Min: -123.18  Med: 8.37 Max: 47.2
Current: 47.2
-123.18
47.2
Net Margin % 25.64
HOLX's Net Margin % is ranked higher than
94% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. HOLX: 25.64 )
Ranked among companies with meaningful Net Margin % only.
HOLX' s Net Margin % Range Over the Past 10 Years
Min: -135.4  Med: -1.5 Max: 25.64
Current: 25.64
-135.4
25.64
ROE % 31.67
HOLX's ROE % is ranked higher than
95% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. HOLX: 31.67 )
Ranked among companies with meaningful ROE % only.
HOLX' s ROE % Range Over the Past 10 Years
Min: -60.17  Med: -0.73 Max: 31.67
Current: 31.67
-60.17
31.67
ROA % 9.86
HOLX's ROA % is ranked higher than
78% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. HOLX: 9.86 )
Ranked among companies with meaningful ROA % only.
HOLX' s ROA % Range Over the Past 10 Years
Min: -32.08  Med: -0.35 Max: 9.86
Current: 9.86
-32.08
9.86
ROC (Joel Greenblatt) % 180.08
HOLX's ROC (Joel Greenblatt) % is ranked higher than
98% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. HOLX: 180.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HOLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -369.68  Med: 25.23 Max: 180.08
Current: 180.08
-369.68
180.08
3-Year Revenue Growth Rate 2.20
HOLX's 3-Year Revenue Growth Rate is ranked lower than
58% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. HOLX: 2.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HOLX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.1  Med: 10.3 Max: 41.9
Current: 2.2
-14.1
41.9
GuruFocus has detected 1 Warning Sign with Hologic Inc $HOLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HOLX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

HOLX Guru Trades in Q3 2016

Jim Simons 590,018 sh (New)
George Soros 7,236 sh (New)
Joel Greenblatt 103,903 sh (+226.36%)
Steven Cohen 1,315,600 sh (+83.82%)
Pioneer Investments 85,816 sh (+47.17%)
Robert Olstein 187,000 sh (unchged)
Leon Cooperman Sold Out
Ken Fisher Sold Out
Kahn Brothers 1,234,514 sh (-3.33%)
Vanguard Health Care Fund 6,896,300 sh (-5.62%)
Paul Tudor Jones 1,200,000 sh (-8.44%)
» More
Q4 2016

HOLX Guru Trades in Q4 2016

Jim Simons 1,463,618 sh (+148.06%)
Pioneer Investments 173,374 sh (+102.03%)
George Soros Sold Out
Joel Greenblatt Sold Out
Robert Olstein 184,000 sh (-1.60%)
Kahn Brothers 1,197,404 sh (-3.01%)
Steven Cohen 1,142,100 sh (-13.19%)
Vanguard Health Care Fund 3,538,200 sh (-48.69%)
Paul Tudor Jones 500,000 sh (-58.33%)
» More
Q1 2017

HOLX Guru Trades in Q1 2017

Eaton Vance Worldwide Health Sciences Fund 491,712 sh (New)
Vanguard Health Care Fund 3,538,200 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 1,456,318 sh (-0.50%)
Pioneer Investments 172,100 sh (-0.73%)
Robert Olstein 167,000 sh (-9.24%)
Kahn Brothers 918,399 sh (-23.30%)
» More
Q2 2017

HOLX Guru Trades in Q2 2017

Lee Ainslie 88,510 sh (New)
Joel Greenblatt 41,201 sh (New)
Caxton Associates 13,100 sh (New)
Chuck Royce 20,000 sh (New)
Vanguard Health Care Fund 3,538,200 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 491,712 sh (unchged)
Kahn Brothers 799,465 sh (-12.95%)
Jim Simons 1,227,118 sh (-15.74%)
Pioneer Investments 94,897 sh (-44.86%)
Robert Olstein 91,500 sh (-45.21%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Kahn Brothers 2017-06-30 Reduce -12.95%0.87%$42.23 - $46.49 $ 37.38-15%799,465
Robert Olstein 2017-06-30 Reduce -45.21%0.41%$42.23 - $46.49 $ 37.38-15%91,500
Joel Greenblatt 2017-06-30 New Buy0.03%$42.23 - $46.49 $ 37.38-15%41,201
Kahn Brothers 2017-03-31 Reduce -23.30%1.89%$39.03 - $42.78 $ 37.38-8%918,399
Robert Olstein 2017-03-31 Reduce -9.24%0.09%$39.03 - $42.78 $ 37.38-8%167,000
Vanguard Health Care Fund 2016-12-31 Reduce -48.69%0.28%$35.37 - $40.79 $ 37.38-3%3,538,200
Kahn Brothers 2016-12-31 Reduce -3.01%0.26%$35.37 - $40.79 $ 37.38-3%1,197,404
Robert Olstein 2016-12-31 Reduce -1.60%0.02%$35.37 - $40.79 $ 37.38-3%184,000
George Soros 2016-12-31 Sold Out 0.01%$35.37 - $40.79 $ 37.38-3%0
Joel Greenblatt 2016-12-31 Sold Out 0.05%$35.37 - $40.79 $ 37.38-3%0
Vanguard Health Care Fund 2016-09-30 Reduce -5.62%0.03%$34.44 - $39.03 $ 37.38-1%6,896,300
Kahn Brothers 2016-09-30 Reduce -3.33%0.28%$34.44 - $39.03 $ 37.38-1%1,234,514
Joel Greenblatt 2016-09-30 Add 226.36%0.03%$34.44 - $39.03 $ 37.38-1%103,903
George Soros 2016-09-30 New Buy0.01%$34.44 - $39.03 $ 37.38-1%7,236
Leon Cooperman 2016-09-30 Sold Out 0.1%$34.44 - $39.03 $ 37.38-1%0
Ken Fisher 2016-09-30 Sold Out $34.44 - $39.03 $ 37.38-1%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334517    SIC: 3844
Compare:NYSE:RMD, NYSE:COO, NAS:XRAY, NYSE:WAT, NYSE:WST, NYSE:MTD, NYSE:HRC, NAS:ICUI, NAS:PODD, NYSE:CMD, NYSE:HAE, NAS:MMSI, NYSE:HYH, NAS:NXTM, NYSE:GKOS, NAS:OSUR, NAS:ATRI, NAS:IRTC, NAS:LMNX, NAS:ATRC » details
Traded in other countries:HOLX.Austria, HO1.Germany,
Headquarter Location:USA
Hologic Inc develops, manufactures and supplies diagnostics products, medical imaging systems and surgical products for women's health. Its products are used in diagnosis of human diseases and screen donated human blood and plasma.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (47% of sales), breast health (37%), surgical (12%), and skeletal health (4%). While the company traditionally focused on breast health, the recent acquisition of Gen-Probe puts a much greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%) and Asia (8%). Hologic is headquartered in Bedford, Massachusetts.

Top Ranked Articles about Hologic Inc

Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic Announces FDA Clearance of Aptima® Assay to Detect Herpes Simplex Virus 1 & 2
Hologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure® for Non-Invasive Body Contouring (Lipolysis) of Back, Inner and Outer Thighs
FDA Approves Hologic's Genius™ 3D Mammography™ Exam as the Only Mammogram Superior for Women with Dense Breasts*
Eaton Vance Worldwide Health Sciences Fund Adds 4 Stocks to Portfolio Health care fund reports fourth-quarter activity
Jason Kritzer, vice president of Eaton Vance Management, invests in companies with a bottom-up, proprietary research approach. The portfolio manager of the Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) invested in four companies during the first quarter: Aetna Inc. (NYSE:AET), Humana Inc. (NYSE:HUM), Hologic Inc. (NASDAQ:HOLX) and Teleflex Inc. (NYSE:TFX) Read more...
Charles J. Dockendorff Elected to Hologic Board of Directors
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2017 on Wednesday, May 10, 2017
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2042 are Eligible to Convert

Ratios

vs
industry
vs
history
PE Ratio 13.98
HOLX's PE Ratio is ranked higher than
79% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. HOLX: 13.98 )
Ranked among companies with meaningful PE Ratio only.
HOLX' s PE Ratio Range Over the Past 10 Years
Min: 13.93  Med: 52.36 Max: 472.67
Current: 13.98
13.93
472.67
Forward PE Ratio 17.01
HOLX's Forward PE Ratio is ranked higher than
84% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.25 vs. HOLX: 17.01 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 13.98
HOLX's PE Ratio without NRI is ranked higher than
79% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. HOLX: 13.98 )
Ranked among companies with meaningful PE Ratio without NRI only.
HOLX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.93  Med: 52.36 Max: 472.67
Current: 13.98
13.93
472.67
Price-to-Owner-Earnings 14.63
HOLX's Price-to-Owner-Earnings is ranked higher than
89% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.16 vs. HOLX: 14.63 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HOLX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.31  Med: 24.16 Max: 336.89
Current: 14.63
8.31
336.89
PB Ratio 3.65
HOLX's PB Ratio is ranked lower than
64% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. HOLX: 3.65 )
Ranked among companies with meaningful PB Ratio only.
HOLX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 2.01 Max: 5.65
Current: 3.65
0.59
5.65
PS Ratio 3.57
HOLX's PS Ratio is ranked lower than
59% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. HOLX: 3.57 )
Ranked among companies with meaningful PS Ratio only.
HOLX' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 2.93 Max: 5.55
Current: 3.57
1.47
5.55
Price-to-Operating-Cash-Flow 163.54
HOLX's Price-to-Operating-Cash-Flow is ranked higher than
59% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.25 vs. HOLX: 163.54 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HOLX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.51  Med: 13.15 Max: 201.44
Current: 163.54
5.51
201.44
EV-to-EBIT 9.26
HOLX's EV-to-EBIT is ranked higher than
87% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. HOLX: 9.26 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -137.4  Med: 24.95 Max: 153.7
Current: 9.26
-137.4
153.7
EV-to-EBITDA 7.06
HOLX's EV-to-EBITDA is ranked higher than
88% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. HOLX: 7.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
HOLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -344.2  Med: 12.8 Max: 100.6
Current: 7.06
-344.2
100.6
Current Ratio 0.85
HOLX's Current Ratio is ranked lower than
95% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. HOLX: 0.85 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.87 Max: 7.31
Current: 0.85
0.85
7.31
Quick Ratio 0.65
HOLX's Quick Ratio is ranked lower than
88% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. HOLX: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 2.28 Max: 6.57
Current: 0.65
0.65
6.57
Days Inventory 82.61
HOLX's Days Inventory is ranked higher than
75% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. HOLX: 82.61 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s Days Inventory Range Over the Past 10 Years
Min: 65.34  Med: 88.04 Max: 108.2
Current: 82.61
65.34
108.2
Days Sales Outstanding 63.67
HOLX's Days Sales Outstanding is ranked higher than
54% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. HOLX: 63.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.15  Med: 60.73 Max: 75.51
Current: 63.67
56.15
75.51
Days Payable 39.51
HOLX's Days Payable is ranked lower than
51% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. HOLX: 39.51 )
Ranked among companies with meaningful Days Payable only.
HOLX' s Days Payable Range Over the Past 10 Years
Min: 21.81  Med: 27.28 Max: 45.11
Current: 39.51
21.81
45.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
HOLX's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. HOLX: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HOLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.1  Med: -6.1 Max: -0.7
Current: -0.7
-53.1
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.73
HOLX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
63% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. HOLX: 1.73 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HOLX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.7 Max: 13.86
Current: 1.73
0.45
13.86
Price-to-Median-PS-Value 1.22
HOLX's Price-to-Median-PS-Value is ranked lower than
71% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. HOLX: 1.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HOLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.81 Max: 2.58
Current: 1.22
0.15
2.58
Earnings Yield (Greenblatt) % 10.79
HOLX's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. HOLX: 10.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HOLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -49.1  Med: 2.5 Max: 10.82
Current: 10.79
-49.1
10.82
Forward Rate of Return (Yacktman) % 25.98
HOLX's Forward Rate of Return (Yacktman) % is ranked higher than
87% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. HOLX: 25.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HOLX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.4  Med: 6.9 Max: 72.7
Current: 25.98
0.4
72.7

More Statistics

Revenue (TTM) (Mil) $2,982.80
EPS (TTM) $ 2.68
Beta0.52
Short Percentage of Float4.69%
52-Week Range $35.15 - 46.80
Shares Outstanding (Mil)280.01

Analyst Estimate

Sep17 Sep18 Sep19 Sep20
Revenue (Mil $) 3,047 3,327 3,530 3,722
EPS ($) 1.97 2.20 2.37 2.60
EPS without NRI ($) 1.97 2.20 2.37 2.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.66%
Dividends per Share ($)
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Hologic to Webcast Presentations at Upcoming Investor Conferences Jul 31 2017 
Hologic Announces FDA Clearance of Aptima® Assay to Detect Herpes Simplex Virus 1 & 2 Jun 20 2017 
Hologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure® for Non-Invasive Bod Jun 15 2017 
FDA Approves Hologic's Genius™ 3D Mammography™ Exam as the Only Mammogram Superior for Women wit Jun 07 2017 
Eaton Vance Worldwide Health Sciences Fund Adds 4 Companies May 17 2017 
Charles J. Dockendorff Elected to Hologic Board of Directors May 16 2017 
Hologic to Webcast Presentations at Upcoming Investor Conferences May 08 2017 
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2017 on Wednesday, May 10, 20 Apr 04 2017 
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2042 are Eligibl Apr 03 2017 
Robert Olstein's Best Performing Investments Include eBay Aug 14 2016 

More From Other Websites
See what the IHS Markit Score report has to say about Hologic Inc. Aug 17 2017
Edited Transcript of HOLX earnings conference call or presentation 2-Aug-17 8:30pm GMT Aug 11 2017
Hologic, Inc. – Value Analysis (NASDAQ:HOLX) : August 12, 2017 Aug 11 2017
Earnings Review and Free Research Report: Stryker’s Net Sales Grew 6.1%; Adjusted Earnings Jumped... Aug 09 2017
Teva and 3D Systems slide while Kellogg and Tesla jump Aug 03 2017
Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance Aug 03 2017
Hologic tops Street 3Q forecasts Aug 02 2017
Hologic Announces Financial Results for Third Quarter of Fiscal 2017 Aug 02 2017
Investor Network: Hologic, Inc. to Host Earnings Call Aug 02 2017
MedTech Stock Earnings Slated for Aug 2: CAH, HOLX & More Aug 01 2017
Hologic to Webcast Presentations at Upcoming Investor Conferences Jul 31 2017
Hologic, Inc. breached its 50 day moving average in a Bearish Manner : HOLX-US : July 28, 2017 Jul 28 2017
ETFs with exposure to Hologic, Inc. : July 24, 2017 Jul 24 2017
What's in the Offing for Hologic (HOLX) in Q3 Earnings? Jul 24 2017
Inside Abiomed’s Profit Margin Expectations for Fiscal 2018 Jul 21 2017
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright... Jul 10 2017
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2017 on Wednesday, August 2,... Jul 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}